A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases
Aim: Real-world evidence comparing healthcare resource utilization (HRU) and costs between ibrutinib and acalabrutinib, two Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) is limited. Materials & methods: Commercial...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Becaris Publishing Limited
2025-04-01
|
| Series: | Journal of Comparative Effectiveness Research |
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850156687523053568 |
|---|---|
| author | Kerry A Rogers Benyam Muluneh Zaina P Qureshi Jinghua He Alex Bokun Zhijie Ding Marie-Helene Lafeuille Priyanka Gogna Bruno Emond Michael Fradley |
| author_facet | Kerry A Rogers Benyam Muluneh Zaina P Qureshi Jinghua He Alex Bokun Zhijie Ding Marie-Helene Lafeuille Priyanka Gogna Bruno Emond Michael Fradley |
| author_sort | Kerry A Rogers |
| collection | DOAJ |
| description | Aim: Real-world evidence comparing healthcare resource utilization (HRU) and costs between ibrutinib
and acalabrutinib, two Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic
leukemia and small lymphocytic lymphoma (CLL/SLL) is limited. Materials & methods: Commercial claims
from IQVIA PharMetrics Plus and electronic medical records from Acentrus were used to separately
evaluate HRU and costs in CLL/SLL patients initiating first-line (1L) single-agent ibrutinib or acalabrutinib
on or after 21 November 2019 (index date). Imputed costs were used for Acentrus using previously
published assumptions. Regression analyses adjusted for baseline characteristics were used to compare
HRU and costs between ibrutinib and acalabrutinib during 1L therapy. Results: In IQVIA, 537 and 355
patients initiated 1L ibrutinib and acalabrutinib, respectively; in Acentrus, 710 and 373 patients initiated
1L ibrutinib and acalabrutinib, respectively. The mean duration of 1L (in years) was longer for ibrutinib
(IQVIA: 1.2; Acentrus: 1.3) than acalabrutinib (IQVIA: 0.8; Acentrus: 0.9). The number of CLL/SLL-related
outpatient visits were significantly lower for ibrutinib versus acalabrutinib (IQVIA: 0.86 vs 1.09 per-patientper-
month, rate ratio: 0.85, p = 0.018; Acentrus: 0.57 vs 0.74 per-patient-per-month, rate ratio: 0.80,
p = 0.036). Using claims data for IQVIA and imputed costs for Acentrus, total all-cause costs (IQVIA: mean
monthly cost difference [MMCD]: -$764, p = 0.279; Acentrus: MMCD: -$1355, p = 0.004) and CLL/SLL related
costs (IQVIA: MMCD: -$649, p = 0.133; Acentrus: MMCD: -$1215, p = 0.004) were lower for ibrutinib versus
acalabrutinib. Conclusion: In this large real-world study using a mix of claims data and imputed cost
estimates, CLL/SLL patients treated with ibrutinib had longer duration of 1L, fewer days with CLL/SLLrelated
outpatient services and numerically lower all-cause and CLL/SLL-related costs versus acalabrutinib,
showing that ibrutinib can be an optimal cost-effective option in 1L. |
| format | Article |
| id | doaj-art-c2ca80ffc1b9414c828371c1d03a8cfd |
| institution | OA Journals |
| issn | 2042-6313 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Becaris Publishing Limited |
| record_format | Article |
| series | Journal of Comparative Effectiveness Research |
| spelling | doaj-art-c2ca80ffc1b9414c828371c1d03a8cfd2025-08-20T02:24:25ZengBecaris Publishing LimitedJournal of Comparative Effectiveness Research2042-63132025-04-0114610.57264/cer-2024-0210A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databasesKerry A Rogers0https://orcid.org/0000-0001-5748-7874Benyam Muluneh1https://orcid.org/0000-0002-2387-6676Zaina P Qureshi2https://orcid.org/0000-0001-9605-3980Jinghua He3Alex Bokun4Zhijie Ding5Marie-Helene Lafeuille6Priyanka Gogna7https://orcid.org/0000-0002-4462-8591Bruno Emond8https://orcid.org/0000-0002-0060-765XMichael Fradley9Division of Hematology, The Ohio State University, Columbus, OH 43210, USAEshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USAJanssen Scientific Affairs, LLC, a Johnson & Johnson company, Horsham, PA 19044, USAJanssen Scientific Affairs, LLC, a Johnson & Johnson company, Horsham, PA 19044, USAJanssen Scientific Affairs, LLC, a Johnson & Johnson company, Horsham, PA 19044, USAJanssen Scientific Affairs, LLC, a Johnson & Johnson company, Horsham, PA 19044, USAAnalysis Group, Inc., Montreal, QC H3B 0G7, CanadaAnalysis Group, Inc., Montreal, QC H3B 0G7, CanadaAnalysis Group, Inc., Montreal, QC H3B 0G7, CanadaThalheimer Center for Cardio-Oncology, Abramson Cancer Center & Division of Cardiology, Hospital of the University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USAAim: Real-world evidence comparing healthcare resource utilization (HRU) and costs between ibrutinib and acalabrutinib, two Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) is limited. Materials & methods: Commercial claims from IQVIA PharMetrics Plus and electronic medical records from Acentrus were used to separately evaluate HRU and costs in CLL/SLL patients initiating first-line (1L) single-agent ibrutinib or acalabrutinib on or after 21 November 2019 (index date). Imputed costs were used for Acentrus using previously published assumptions. Regression analyses adjusted for baseline characteristics were used to compare HRU and costs between ibrutinib and acalabrutinib during 1L therapy. Results: In IQVIA, 537 and 355 patients initiated 1L ibrutinib and acalabrutinib, respectively; in Acentrus, 710 and 373 patients initiated 1L ibrutinib and acalabrutinib, respectively. The mean duration of 1L (in years) was longer for ibrutinib (IQVIA: 1.2; Acentrus: 1.3) than acalabrutinib (IQVIA: 0.8; Acentrus: 0.9). The number of CLL/SLL-related outpatient visits were significantly lower for ibrutinib versus acalabrutinib (IQVIA: 0.86 vs 1.09 per-patientper- month, rate ratio: 0.85, p = 0.018; Acentrus: 0.57 vs 0.74 per-patient-per-month, rate ratio: 0.80, p = 0.036). Using claims data for IQVIA and imputed costs for Acentrus, total all-cause costs (IQVIA: mean monthly cost difference [MMCD]: -$764, p = 0.279; Acentrus: MMCD: -$1355, p = 0.004) and CLL/SLL related costs (IQVIA: MMCD: -$649, p = 0.133; Acentrus: MMCD: -$1215, p = 0.004) were lower for ibrutinib versus acalabrutinib. Conclusion: In this large real-world study using a mix of claims data and imputed cost estimates, CLL/SLL patients treated with ibrutinib had longer duration of 1L, fewer days with CLL/SLLrelated outpatient services and numerically lower all-cause and CLL/SLL-related costs versus acalabrutinib, showing that ibrutinib can be an optimal cost-effective option in 1L.acalabrutinibchronic lymphocytic leukemiaclaims datacost comparisoncostsemrhealthcare resource useibrutinibreal-world studysmall lymphocytic lymphoma |
| spellingShingle | Kerry A Rogers Benyam Muluneh Zaina P Qureshi Jinghua He Alex Bokun Zhijie Ding Marie-Helene Lafeuille Priyanka Gogna Bruno Emond Michael Fradley A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases Journal of Comparative Effectiveness Research acalabrutinib chronic lymphocytic leukemia claims data cost comparison costs emr healthcare resource use ibrutinib real-world study small lymphocytic lymphoma |
| title | A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases |
| title_full | A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases |
| title_fullStr | A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases |
| title_full_unstemmed | A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases |
| title_short | A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases |
| title_sort | comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first line ibrutinib or acalabrutinib using two large us real world databases |
| topic | acalabrutinib chronic lymphocytic leukemia claims data cost comparison costs emr healthcare resource use ibrutinib real-world study small lymphocytic lymphoma |
| work_keys_str_mv | AT kerryarogers acomparisonofhealthcareresourceutilizationandcostsbetweenpatientswithchroniclymphocyticleukemiatreatedwithfirstlineibrutiniboracalabrutinibusingtwolargeusrealworlddatabases AT benyammuluneh acomparisonofhealthcareresourceutilizationandcostsbetweenpatientswithchroniclymphocyticleukemiatreatedwithfirstlineibrutiniboracalabrutinibusingtwolargeusrealworlddatabases AT zainapqureshi acomparisonofhealthcareresourceutilizationandcostsbetweenpatientswithchroniclymphocyticleukemiatreatedwithfirstlineibrutiniboracalabrutinibusingtwolargeusrealworlddatabases AT jinghuahe acomparisonofhealthcareresourceutilizationandcostsbetweenpatientswithchroniclymphocyticleukemiatreatedwithfirstlineibrutiniboracalabrutinibusingtwolargeusrealworlddatabases AT alexbokun acomparisonofhealthcareresourceutilizationandcostsbetweenpatientswithchroniclymphocyticleukemiatreatedwithfirstlineibrutiniboracalabrutinibusingtwolargeusrealworlddatabases AT zhijieding acomparisonofhealthcareresourceutilizationandcostsbetweenpatientswithchroniclymphocyticleukemiatreatedwithfirstlineibrutiniboracalabrutinibusingtwolargeusrealworlddatabases AT mariehelenelafeuille acomparisonofhealthcareresourceutilizationandcostsbetweenpatientswithchroniclymphocyticleukemiatreatedwithfirstlineibrutiniboracalabrutinibusingtwolargeusrealworlddatabases AT priyankagogna acomparisonofhealthcareresourceutilizationandcostsbetweenpatientswithchroniclymphocyticleukemiatreatedwithfirstlineibrutiniboracalabrutinibusingtwolargeusrealworlddatabases AT brunoemond acomparisonofhealthcareresourceutilizationandcostsbetweenpatientswithchroniclymphocyticleukemiatreatedwithfirstlineibrutiniboracalabrutinibusingtwolargeusrealworlddatabases AT michaelfradley acomparisonofhealthcareresourceutilizationandcostsbetweenpatientswithchroniclymphocyticleukemiatreatedwithfirstlineibrutiniboracalabrutinibusingtwolargeusrealworlddatabases AT kerryarogers comparisonofhealthcareresourceutilizationandcostsbetweenpatientswithchroniclymphocyticleukemiatreatedwithfirstlineibrutiniboracalabrutinibusingtwolargeusrealworlddatabases AT benyammuluneh comparisonofhealthcareresourceutilizationandcostsbetweenpatientswithchroniclymphocyticleukemiatreatedwithfirstlineibrutiniboracalabrutinibusingtwolargeusrealworlddatabases AT zainapqureshi comparisonofhealthcareresourceutilizationandcostsbetweenpatientswithchroniclymphocyticleukemiatreatedwithfirstlineibrutiniboracalabrutinibusingtwolargeusrealworlddatabases AT jinghuahe comparisonofhealthcareresourceutilizationandcostsbetweenpatientswithchroniclymphocyticleukemiatreatedwithfirstlineibrutiniboracalabrutinibusingtwolargeusrealworlddatabases AT alexbokun comparisonofhealthcareresourceutilizationandcostsbetweenpatientswithchroniclymphocyticleukemiatreatedwithfirstlineibrutiniboracalabrutinibusingtwolargeusrealworlddatabases AT zhijieding comparisonofhealthcareresourceutilizationandcostsbetweenpatientswithchroniclymphocyticleukemiatreatedwithfirstlineibrutiniboracalabrutinibusingtwolargeusrealworlddatabases AT mariehelenelafeuille comparisonofhealthcareresourceutilizationandcostsbetweenpatientswithchroniclymphocyticleukemiatreatedwithfirstlineibrutiniboracalabrutinibusingtwolargeusrealworlddatabases AT priyankagogna comparisonofhealthcareresourceutilizationandcostsbetweenpatientswithchroniclymphocyticleukemiatreatedwithfirstlineibrutiniboracalabrutinibusingtwolargeusrealworlddatabases AT brunoemond comparisonofhealthcareresourceutilizationandcostsbetweenpatientswithchroniclymphocyticleukemiatreatedwithfirstlineibrutiniboracalabrutinibusingtwolargeusrealworlddatabases AT michaelfradley comparisonofhealthcareresourceutilizationandcostsbetweenpatientswithchroniclymphocyticleukemiatreatedwithfirstlineibrutiniboracalabrutinibusingtwolargeusrealworlddatabases |